Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Barker

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Journal of Medicinal Chemistry|August 6, 2019
Profile of a Highly Selective Quaternized Pyrrolidine Betaine α<sub>v</sub>β<sub>6</sub> Integrin Inhibitor-(3<i>S</i>)-3-(3-(3,5-Dimethyl-1<i>H</i>-pyrazol-1-yl)phenyl)-4-((1<i>S</i> and 1<i>R</i>,3<i>R</i>)-1-methyl-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-ium-1-yl)butanoate Synthesized by Stereoselective MethylationTim N Barrett, Jonathan A Taylor, Daniel Barker, et al.
Emergency Medicine Australasia : EMA|March 16, 2019
Driving change: A partnership study protocol using shared emergency department data to reduce alcohol-related harmPeter Miller, Nicolas Droste, Diana Egerton-Warburton, et al.
International Journal of Cancer|September 19, 2012
Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriersBente A Talseth-Palmer, Juul T Wijnen, Ingvild S Brenne, et al.
Frontiers in Stroke|January 16, 2026
Rollout of a statewide Australian telestroke network including virtual reality training is associated with improved hyperacute stroke workflow metrics and thrombolysis rateCarlos Garcia-Esperon, Steven Maltby, Ken Butcher, et al.
Asia-Pacific Journal of Clinical Oncology|February 1, 2025
A Comparison of Australian Oncology Clinicians' Smoking Cessation Care Practices for People Who Currently Smoke Versus Those Who Report Recently Stopping SmokingAlison Luk Young, Melissa McEnallay, Fiona Day, et al.
Australian and New Zealand Journal of Public Health|September 19, 2022
Most common principal diagnoses assigned to Australian emergency department presentations involving alcohol use: a multi-centre studyPeter Miller, Thea Vakidis, Nicholas Taylor, et al.
Implementation Science : IS|March 24, 2026
Ready to screen implementation trial protocol: a cluster randomized implementation trial comparing a bundled implementation strategy versus a simple implementation strategy to improve intention to screen in the Australian National Lung Cancer Screening ProgramDzenana Kartal, Christine Paul, Georgia Bartlett, et al.
Trends in Ecology & Evolution|October 8, 2011
What do we need to know about speciation?, Roger Butlin, Allan Debelle, et al.
Journal of Medicinal Chemistry|December 20, 2021
Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase MetabolismChristopher R Wellaway, Ian R Baldwin, Paul Bamborough, et al.
Journal of Medicinal Chemistry|April 13, 2026
Automated Molecular Design in BRADSHAW, Applied to the Optimization of ERAP1 InhibitorsRobert P Law, Ian D Wall, Richard Lonsdale, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Journal of Medicinal Chemistry|August 6, 2019
Profile of a Highly Selective Quaternized Pyrrolidine Betaine α<sub>v</sub>β<sub>6</sub> Integrin Inhibitor-(3<i>S</i>)-3-(3-(3,5-Dimethyl-1<i>H</i>-pyrazol-1-yl)phenyl)-4-((1<i>S</i> and 1<i>R</i>,3<i>R</i>)-1-methyl-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-ium-1-yl)butanoate Synthesized by Stereoselective MethylationTim N Barrett, Jonathan A Taylor, Daniel Barker, et al.
Emergency Medicine Australasia : EMA|March 16, 2019
Driving change: A partnership study protocol using shared emergency department data to reduce alcohol-related harmPeter Miller, Nicolas Droste, Diana Egerton-Warburton, et al.
International Journal of Cancer|September 19, 2012
Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriersBente A Talseth-Palmer, Juul T Wijnen, Ingvild S Brenne, et al.
Frontiers in Stroke|January 16, 2026
Rollout of a statewide Australian telestroke network including virtual reality training is associated with improved hyperacute stroke workflow metrics and thrombolysis rateCarlos Garcia-Esperon, Steven Maltby, Ken Butcher, et al.
Asia-Pacific Journal of Clinical Oncology|February 1, 2025
A Comparison of Australian Oncology Clinicians' Smoking Cessation Care Practices for People Who Currently Smoke Versus Those Who Report Recently Stopping SmokingAlison Luk Young, Melissa McEnallay, Fiona Day, et al.
Australian and New Zealand Journal of Public Health|September 19, 2022
Most common principal diagnoses assigned to Australian emergency department presentations involving alcohol use: a multi-centre studyPeter Miller, Thea Vakidis, Nicholas Taylor, et al.
Implementation Science : IS|March 24, 2026
Ready to screen implementation trial protocol: a cluster randomized implementation trial comparing a bundled implementation strategy versus a simple implementation strategy to improve intention to screen in the Australian National Lung Cancer Screening ProgramDzenana Kartal, Christine Paul, Georgia Bartlett, et al.
Trends in Ecology & Evolution|October 8, 2011
What do we need to know about speciation?, Roger Butlin, Allan Debelle, et al.
Journal of Medicinal Chemistry|December 20, 2021
Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase MetabolismChristopher R Wellaway, Ian R Baldwin, Paul Bamborough, et al.
Journal of Medicinal Chemistry|April 13, 2026
Automated Molecular Design in BRADSHAW, Applied to the Optimization of ERAP1 InhibitorsRobert P Law, Ian D Wall, Richard Lonsdale, et al.
Pageof 14